Abstract
ABSTRACT Cisplatin is used to treat a variety of solid tumors, including those of the head, neck, breast, testis, and ovary. Clinically, nephrotoxicity can occur in 20% to 35% of cisplatin-receiving patients. Research has demonstrated that the levels of cisplatin in maternal blood and umbilical cord blood are approximately the same. Propolis is produced by bees and has antioxidant and anti-inflammatory properties. Therefore, this study aims to evaluate the potential therapeutic role of propolis extract (PE) against cisplatin-induced nephrotoxicity in female rats and their pups. Thirty-two pregnant rats were divided into four groups: control, PE, cisplatin-treated, and cisplatin + PE groups. Cisplatin was injected at gestation days 7 and 14, followed by treatment with PE from gestational day 20 until the end of weaning. The blood samples were collected, and the kidneys were removed from the mother’s rat and their pups. Supplementation of PE to cisplatin-given mothers and their fetuses showed remarkable reduction of oxidative stress, inflammation, and disrupted renal functions induced by cisplatin. This was manifested by a significant decline in elevated serum malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), cystatin-C levels, urea, creatinine, and uric acid, and a significant rise in superoxide dismutase (SOD) and catalase (CAT), and glutathione peroxidase (GPx). This is associated with the restoration of the kidney histopathological alterations induced by cisplatin. Additionally, PE suppressed caspase-3, and up-regulated proliferating cell nuclear antigen (PCNA) activities in the kidney tissues. Propolis extract attenuated the nephrotoxicity induced by cisplatin in female rats and their fetuses through combating oxidative stress and pathophysiological changes induced by cisplatin.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call